Table 1.
Basic information of all patients participated in this study
| Items | Minimum | Maximum | x ± SD |
|---|---|---|---|
| Gender | Male(88.8%) | Female(11.2%) | |
| Age | 22 | 80 | 50.80 ± 12.18 |
| Hepatitis (0 = none, 1 = yes) | Yes (91%) | No(9%) | |
| OXA manufacturers (0 = import, 1 = domestic) | Import (60%) | Domestic (40%) | |
| BLCL staging (1 = B stage, 0 = C period) | B(14%) | C(86%) | |
| Child Pugh classification (0 = A level, 1 = B level, 2 = C level) | A(88%) | B(12%) | |
| Catheter arterial diameter(mm) | 1 | 4.5 | 2.67 ± 0.93 |
| OXA preparation time | Less than 4 h (59%) | More than 4 h (41%) | |
| Hepatic artery diameter (mm) | 2.7 | 4.5 | 3.50 ± 0.52 |
| Useage of Microcatheter | No(52%) | Yes(48%) | |
| VAS score | 0 | 10 | 3.60 ± 3.36 |
| Useage of lidocaine | No (57%) | Yes (43%) | |
| Effectivity of lidocaine | No effectivity (4%) | Effectivity (96%) |